

Yasuhiro Tsutani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1838114/publications.pdf>

Version: 2024-02-01

140
papers

2,737
citations

236833

25
h-index

214721

47
g-index

141
all docs

141
docs citations

141
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma. <i>Chest</i> , 2014, 145, 66-71.	0.4	280
2	Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 607-612.	0.4	195
3	Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: Propensity score-matched analysis in a multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 358-364.	0.4	176
4	Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 1365-1371.	0.4	117
5	Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: Prognostic comparison using high-resolution computed tomography findings. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 17-23.	0.4	105
6	Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1469-1480.	0.4	83
7	The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 580-585.	0.4	77
8	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 451-459.	0.9	76
9	Surgical Outcomes of Complex Versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1032-1039.	0.7	72
10	Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1958-1965.	0.7	66
11	Difference in Prognostic Significance of Maximum Standardized Uptake Value on [18F]-Fluoro-2-Deoxyglucose Positron Emission Tomography Between Adenocarcinoma and Squamous Cell Carcinoma of the Lung. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 890-896.	0.6	59
12	Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1112-1118.	0.6	57
13	Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 114-121.	0.6	56
14	Radical hybrid video-assisted thoracic segmentectomy: long-term results of minimally invasive anatomical sublobar resection for treating lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 14, 5-11.	0.5	50
15	Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma. <i>Annals of Cardiothoracic Surgery</i> , 2014, 3, 153-9.	0.6	48
16	Prognostic Role of Subtype Classification in Small-Sized Pathologic NO Invasive Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1668-1673.	0.7	46
17	Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1089-1096.e1.	0.4	42
18	Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 637-642.	0.6	40

#	ARTICLE	IF	CITATIONS
19	Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 366-371.	0.6	40
20	Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 281-290.	0.4	35
21	Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1820-1826.	0.4	33
22	Sublobar Resection for Lung Adenocarcinoma Meeting Node-Negative Criteria on Preoperative Imaging. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1701-1707.	0.7	33
23	Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1179-1185.	0.4	33
24	Positive EGFR mutation status is a risk of recurrence in pN0 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. <i>Lung Cancer</i> , 2020, 141, 107-113.	0.9	33
25	Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles. <i>Cancer Science</i> , 2020, 111, 2104-2115.	1.7	32
26	Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1244-1252.e1.	0.4	27
27	Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-b N0 M0 Lung Cancer. <i>World Journal of Surgery</i> , 2018, 42, 2493-2501.	0.8	26
28	High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1484-1490.	0.7	26
29	Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	1.0	25
30	Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces. <i>Annals of Thoracic Surgery</i> , 2021, 112, 935-943.	0.7	25
31	Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1608-1616.	0.7	25
32	Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm. <i>Clinical Lung Cancer</i> , 2020, 21, e528-e538.	1.1	24
33	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231116.	1.1	22
34	Wedge resection versus segmentectomy in patients with stage I non-small-cell lung cancer unfit for lobectomy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1134-1142.	0.6	20
35	Predicting Severe Postoperative Complication in Patients With Lung Cancer and Interstitial Pneumonia. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1054-1060.	0.7	20
36	What are the radiologic findings predictive of indolent lung adenocarcinoma?. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 367-372.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Increased risk of recurrence in resected EGFR-positive pNOMO invasive lung adenocarcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1594-1602.	0.8	19
38	Prognosis of segmentectomy and lobectomy for radiologically aggressive small-sized lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1245-1253.	0.6	19
39	Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1076-1079.	0.6	19
40	Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1896-1901.	0.7	17
41	Postoperative Recurrence and Survival After Segmentectomy for Clinical Stage 0 or IA Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 397-403.e1.	1.1	17
42	Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 485-492.	1.2	17
43	Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 1022-1026.	0.6	16
44	Prediction of Lymph Node Metastasis Using Semiquantitative Evaluation of PET for Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1036-1042.	0.7	16
45	Guanylate binding protein 1 (GBP-1) promotes cell motility and invasiveness of lung adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 266-272.	1.0	15
46	Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1530-1536.	0.7	15
47	Systematic Versus Lobe-Specific Mediastinal Lymphadenectomy for Hypermetabolic Lung Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7162-7171.	0.7	14
48	The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1306-1315.e4.	0.4	14
49	Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line. <i>Oncology Reports</i> , 2008, 20, 1545-51.	1.2	14
50	Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. <i>Histopathology</i> , 2019, 74, 545-554.	1.6	13
51	Wedge resection as an alternative treatment for octogenarian and older patients with early-stage non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1051-1057.	0.6	12
52	Oncologic Outcomes of Complex Segmentectomy: A Multicenter Propensity Score-Matched Analysis. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1044-1051.	0.7	12
53	Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655651.	1.3	12
54	The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study. <i>Lung Cancer</i> , 2021, 158, 9-14.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component. <i>Annals of Surgical Oncology</i> , 2020, 27, 945-955.	0.7	11
56	Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e302-e314.	1.1	11
57	Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 51, ezw318.	0.6	10
58	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. <i>BMC Cancer</i> , 2018, 18, 1231.	1.1	10
59	Oncologic outcomes of lobectomy vs. segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2020, 12, 3178-3187.	0.6	10
60	Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100126.	0.6	10
61	Postoperative Pulmonary Function After Complex Segmentectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8347-8355.	0.7	10
62	The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	10
63	Prospective feasibility study of sealing pulmonary vessels with energy in lung surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 388-395.	0.4	9
64	Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. <i>Oncotarget</i> , 2017, 8, 108936-108945.	0.8	9
65	Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma. <i>Oncology Letters</i> , 2019, 17, 3607-3614.	0.8	8
66	A multi-institutional randomized phase III trial comparing anatomical segmentectomy and wedge resection for clinical stage IA non-small cell lung cancer in high-risk operable patients: Japan Clinical Oncology Group Study JCOG1909 (ANSWER study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1209-1213.	0.6	8
67	Diagnostic performance of peripheral leukocyte telomere G-tail length for detecting breast cancer. <i>Cancer Science</i> , 2020, 111, 1856-1861.	1.7	8
68	Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 28-36.	0.6	8
69	Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3709-3718.	1.2	8
70	Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	8
71	Non-small-cell lung cancer prognosis using carcinoembryonic antigen levels in pleural lavage fluid. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, e96-e101.	0.6	7
72	Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1 α and glucose transporter 1 in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, hv138.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2325-2333.	1.2	7
74	Surgical Procedure Selection for Stage I Lung Cancer: Complex Segmentectomy versus Wedge Resection. <i>Clinical Lung Cancer</i> , 2021, 22, e224-e233.	1.1	7
75	Patient Selection of Sublobar Resection Using Visual Evaluation of Positron-Emission Tomography (PET) for Early-Stage Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 2068-2075.	0.7	7
76	Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 120-126.e3.	1.1	7
77	Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer. <i>BMC Pulmonary Medicine</i> , 2021, 21, 186.	0.8	7
78	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 333-344.	0.6	6
79	Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1543-1550.	0.7	5
80	Initial experience of robotic anatomical segmentectomy for non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 440-445.	0.6	5
81	Impact of postoperative pleurodesis on pulmonary function after lung segmentectomy. <i>JTCVS Open</i> , 2021, 5, 110-118.	0.2	5
82	Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 10105.	1.6	5
83	Prediction of Acute Exacerbation of Interstitial Pneumonia Using Visual Evaluation of PET. <i>Annals of Thoracic Surgery</i> , 2021, 112, 264-270.	0.7	5
84	Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1561-1569.	0.6	5
85	Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study. <i>Journal of Clinical Oncology</i> , 2019, 37, 8500-8500.	0.8	5
86	Reply to "Lobe-Specific Lymph Node Dissection for Lung Cancer: Is It Still Feasible?" by Han-Yu Deng. <i>Annals of Surgical Oncology</i> , 2021, 28, 848-849.	0.7	5
87	Segmentectomy versus lobectomy for solid predominant cN0 lung cancer: analysis using visual evaluation of positron emission tomography. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 279-286.	0.6	5
88	Pathological high malignant grade is higher risk of recurrence in pNOMO invasive lung adenocarcinoma, even with small invasive size. <i>Thoracic Cancer</i> , 2021, 12, 3141-3149.	0.8	5
89	Appropriate Extent of Lymphadenectomy in Segmentectomy: A Multicenter Study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 451-458.	0.6	5
90	Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 753-759.	0.5	5

#	ARTICLE	IF	CITATIONS
91	Dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in esophageal cancer patients: Correlation with clinicopathological factors and prognosis. <i>Molecular Medicine Reports</i> , 2008, 1, 713-9.	1.1	4
92	Lung metastasis of adenoid cystic carcinoma, which mimicked primary lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 327-329.	0.8	4
93	Investigation of surgical technique for bronchial stump closure after lobectomy in animal model. <i>General Thoracic and Cardiovascular Surgery</i> , 2020, 68, 609-614.	0.4	4
94	Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography. <i>Clinical Lung Cancer</i> , 2021, 22, e431-e437.	1.1	4
95	Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 622742.	1.3	4
96	Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung. <i>General Thoracic and Cardiovascular Surgery</i> , 2015, 63, 153-158.	0.4	3
97	Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers. <i>General Thoracic and Cardiovascular Surgery</i> , 2017, 65, 392-399.	0.4	3
98	Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2021, 10, 766-775.	1.3	3
99	Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL). <i>BMJ Open</i> , 2021, 11, e043234.	0.8	3
100	A Multicenter Study of Complex Segmentectomy versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	3
101	Complete transection of the left main bronchus caused by blunt thoracic trauma in a child treated by bronchoplasty and lung parenchyma preservation. <i>General Thoracic and Cardiovascular Surgery</i> , 2016, 64, 113-115.	0.4	2
102	Bronchoplasties at the Segmental Level. <i>Thoracic Surgery Clinics</i> , 2018, 28, 299-304.	0.4	2
103	Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30Åmm. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1306-1312.	0.6	2
104	Bronchial mucosal ablation for bronchial stump closure in right pneumonectomy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 71.	0.4	2
105	Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1317-1324.	0.7	2
106	Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1617-1623.	0.7	2
107	Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2022, 23, e9-e16.e1.	1.1	2
108	Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pNOMO EGFR-mutant lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1419-1428.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, 433-440.e1.	1.1	1
110	OA15.03 Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease. <i>Journal of Thoracic Oncology</i> , 2017, 12, S302.	0.5	1
111	The differences in histological changes among pulmonary vessels divided with an energy device. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 372-378.	0.5	1
112	Appropriate treatment strategy for ground glass opacity‐dominant non-small cell lung cancer. <i>Video-Assisted Thoracic Surgery</i> , 0, 3, 34-34.	0.1	1
113	Prognostic role of interstitial pneumonia with or without emphysema in patients with clinical stage I lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1123-1131.	0.6	1
114	Techniques of Minimally Invasive Posterior Basal (S10) Segmentectomies of the Lower Lobes. <i>Operative Techniques in Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.2	1
115	Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, , .	0.5	1
116	Reply to the Editor. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1148-1149.	0.4	0
117	Preoperative predictors of distant recurrence in patients with clinical stage IA lung adenocarcinoma undergoing complete resection. <i>Japanese Journal of Clinical Oncology</i> , 2016, 47, 157-163.	0.6	0
118	P1.05-056 Increased Risk of Postoperative Recurrence in EGFR-Positive Stage IA to IB Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S649.	0.5	0
119	Metachronous Lung Cancer After Pleurectomy/Decortication. <i>Annals of Thoracic Surgery</i> , 2019, 107, e1-e3.	0.7	0
120	Reply to Li and Che. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 614-615.	0.6	0
121	ASO Author Reflection: Position of the Complex Segmentectomy on Postoperative Pulmonary Function. <i>Annals of Surgical Oncology</i> , 2021, 28, 8356-8357.	0.7	0
122	ASO Author Reflections: Survival Outcomes between Patients with Hypermetabolic Non-small Cell Lung Cancer Undergoing Systematic and Lobe-Specific Mediastinal Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 7172-7172.	0.7	0
123	Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8554-8554.	0.8	0
124	Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8525-8525.	0.8	0
125	Prediction of lymph node metastasis using 5-point visual scale criteria of [18F]-fluoro-2-deoxy-D-glucose on positron emission tomography / computed tomography for early stage lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21084-e21084.	0.8	0
126	Abstract 1402: Preclinical evaluation of a novel senescence-associated miRNA miR-3140-3p for malignant pleural mesothelioma. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 5594: Immune gene expression by nCounter in mucinous adenocarcinoma lung cancer. , 2020, , .		0
128	Reply to Zhang <i>et al.</i>. European Journal of Cardio-thoracic Surgery, 2021, 59, 928-928.	0.6	0
129	Abstract P3-04-01: Telomere G-tail length correlates with the presence of breast cancer. , 2020, , .		0
130	ASO Author Reflections: Usefulness of Visual Evaluation of PET in Predicting Prognosis after Lung Resection for Early-Stage Lung Adenocarcinoma and Selecting Candidates for Sublobar Resection. Annals of Surgical Oncology, 2021, 28, 2076-2077.	0.7	0
131	Reply to Zhou <i>et al.</i>. European Journal of Cardio-thoracic Surgery, 2022, , .	0.6	0
132	Segmentectomy for STAS positive lung adenocarcinoma. Annals of Thoracic Surgery, 2021, , .	0.7	0
133	Abstract 2577: Circulating micro RNA/isomiRs as novel biomarker of esophageal squamous cell carcinoma. , 2019, , .		0
134	Abstract 2853: Cell motility and invasiveness are promoted by guanylate binding protein 1, GBP-1 in lung adenocarcinoma. , 2019, , .		0
135	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
136	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
137	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
138	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
139	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
140	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0